August 2, 2017: Meeting of the Arthritis Advisory Committee Meeting Announcement - 08/01/2017
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 8, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news

UPDATED PUBLIC PARTICIPATION INFORMATION: August 3, 2017: Meeting of the Arthritis Advisory Committee Meeting Announcement - 08/02/2017
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 8, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news

UPDATED PUBLIC PARTICIPATION INFORMATION: October 13, 2017: Meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee Meeting Announcement - 10/12/2017
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 8, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news

February 14-15, 2018: Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee Meeting Announcement - 02/13/2018
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 8, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news

March 8, 2018: Meeting of the Gastrointestinal Drugs Advisory Committee Meeting Announcement - 03/07/2018
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 8, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news

UPDATED PUBLIC PARTICIPATION INFORMATION: October 11, 2018: Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee Meeting Announcement - 10/10/2018
October 11, 2018: Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee Meeting Announcement (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 8, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA grants accelerated approval to zanubrutinib for relapsed or refractory follicular lymphoma
On March 7, 2024, the Food and Drug Administration granted accelerated approval to zanubrutinib (Brukinsa, BeiGene USA, Inc.) with obinutuzumab for relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 7, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA approves nivolumab in combination with cisplatin and gemcitabine for unresectable or metastatic urothelial carcinoma
On March 6, 2024, the Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Company) in combination with cisplatin and gemcitabine for first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 7, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Food and Drug Omnibus Reform Act (FDORA) of 2022
The Food and Drug Omnibus Reform Act of 2022 (FDORA) requires FDA to develop several different kinds of informational documents, including public reports, reports to Congress, strategic plans, and others. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 7, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA granted accelerated approval to belantamab mafodotin-blmf for multiple myeloma
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 7, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Food and Drug Omnibus Act (FDORA) of 2022
The Food and Drug Omnibus Act of 2022 (FDORA) requires FDA to develop several different kinds of informational documents, including public reports, reports to Congress, strategic plans, and others. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 7, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news

How to Participate in Emerging Technology Program (ETP)
CDER ’s Office of Pharmaceutical Quality created the Emerging Technology Program to promote the adoption of innovative approaches to pharmaceutical product design and manufacturing. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 7, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Benefits of Emerging Technology Program (ETP)
CDER ’s Office of Pharmaceutical Quality created the Emerging Technology Program to promote the adoption of innovative approaches to pharmaceutical product design and manufacturing. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 7, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Lifecycle of an Emerging Technology Program (ETP)
CDER ’s Office of Pharmaceutical Quality created the Emerging Technology Program to promote the adoption of innovative approaches to pharmaceutical product design and manufacturing. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 7, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Emerging Technology Program (ETP)
CDER ’s Office of Pharmaceutical Quality created the Emerging Technology Program to promote the adoption of innovative approaches to pharmaceutical product design and manufacturing. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 7, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news